» Articles » PMID: 33726758

O-GlcNAcylation Homeostasis Controlled by Calcium Influx Channels Regulates Multiple Myeloma Dissemination

Overview
Publisher Biomed Central
Specialty Oncology
Date 2021 Mar 17
PMID 33726758
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple myeloma (MM) cell motility is a critical step during MM dissemination throughout the body, but how it is regulated remains largely unknown. As hypercalcemia is an important clinical feature of MM, high calcium (Ca) and altered Ca signaling could be a key contributing factor to the pathological process.

Methods: Bioinformatics analyses were employed to assess the clinical significance of Ca influx channels in clinical specimens of smoldering and symptomatic MM. Functional and regulatory roles of influx channels and downstream signaling in MM cell migration and invasion were conducted and experimental MM dissemination was examined in a xenograft mouse model using in vivo live imaging and engraftment analysis.

Results: Inhibition of TRPM7, ORAI1, and STIM1 influx channels, which are highly expressed in MM patients, and subsequent blockage of Ca influx by CRISPR/Cas9 and small molecule inhibitors, effectively inhibit MM cell migration and invasion, and attenuate the experimental MM dissemination. Mechanistic studies reveal a nutrient sensor O-GlcNAcylation as a downstream regulator of Ca influx that specifically targets cell adhesion molecules. Hyper-O-GlcNAcylation following the inhibition of Ca influx channels induces integrin α4 and integrin β7 downregulation via ubiquitin-proteasomal degradation and represses the aggressive MM phenotype.

Conclusions: Our findings unveil a novel regulatory mechanism of MM cell motility via Ca influx/O-GlcNAcylation axis that directly targets integrin α4 and integrin β7, providing mechanistic insights into the pathogenesis and progression of MM and demonstrating potential predictive biomarkers and therapeutic targets for advanced MM.

Citing Articles

Role of TRP Channels in Cancer-Induced Bone Pain.

Coluzzi F, Scerpa M, Alessandri E, Romualdi P, Rocco M Int J Mol Sci. 2025; 26(3).

PMID: 39940997 PMC: 11818569. DOI: 10.3390/ijms26031229.


The Role of TRPM7 in Oncogenesis.

Koles L, Ribiczey P, Szebeni A, Kadar K, Zelles T, Zsembery A Int J Mol Sci. 2024; 25(2).

PMID: 38255793 PMC: 10815510. DOI: 10.3390/ijms25020719.


Novel cuproptosis-related lncRNAs can predict the prognosis of patients with multiple myeloma.

Chen Y, Tang J, Chen L, Chen J Transl Cancer Res. 2023; 12(11):3074-3087.

PMID: 38130312 PMC: 10731335. DOI: 10.21037/tcr-23-960.


Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma.

Evers M, Schreder M, Stuhmer T, Jundt F, Ebert R, Hartmann T Blood Cancer J. 2023; 13(1):43.

PMID: 36959208 PMC: 10036560. DOI: 10.1038/s41408-023-00817-7.


On the modulation of TRPM channels: Current perspectives and anticancer therapeutic implications.

Ciaglia T, Vestuto V, Bertamino A, Gonzalez-Muniz R, Gomez-Monterrey I Front Oncol. 2023; 12:1065935.

PMID: 36844925 PMC: 9948629. DOI: 10.3389/fonc.2022.1065935.


References
1.
Oyajobi B . Multiple myeloma/hypercalcemia. Arthritis Res Ther. 2007; 9 Suppl 1:S4. PMC: 1924519. DOI: 10.1186/ar2168. View

2.
Wu J, Chiang M, Hsu P, Tsai D, Hung K, Wang Y . O-GlcNAcylation is required for B cell homeostasis and antibody responses. Nat Commun. 2017; 8(1):1854. PMC: 5707376. DOI: 10.1038/s41467-017-01677-z. View

3.
Bhutani M, Foureau D, Atrash S, Voorhees P, Usmani S . Extramedullary multiple myeloma. Leukemia. 2019; 34(1):1-20. DOI: 10.1038/s41375-019-0660-0. View

4.
Weinstock M, Ghobrial I . Extramedullary multiple myeloma. Leuk Lymphoma. 2012; 54(6):1135-41. DOI: 10.3109/10428194.2012.740562. View

5.
Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E . Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002; 99(5):1745-57. DOI: 10.1182/blood.v99.5.1745. View